Haemonetics Corporation $HAE Shares Sold by William Blair Investment Management LLC

Posted by Brian Himes on May 26th, 2026

William Blair Investment Management LLC lessened its holdings in Haemonetics Corporation (NYSE:HAE – Free Report) by 34.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 314,654 shares of the medical instruments supplier’s stock after selling 162,056 shares during the period. William Blair Investment Management LLC owned approximately 0.68% of Haemonetics worth $25,220,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. AQR Capital Management LLC raised its holdings in shares of Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after buying an additional 1,678,630 shares during the period. Millennium Management LLC increased its stake in Haemonetics by 4,296.3% during the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after purchasing an additional 755,592 shares during the period. Invenomic Capital Management LP increased its stake in Haemonetics by 1,691.5% during the third quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock worth $24,288,000 after purchasing an additional 470,502 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Haemonetics during the third quarter worth about $15,703,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Haemonetics during the third quarter worth about $13,178,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Price Performance

HAE stock opened at $65.48 on Tuesday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The firm has a market capitalization of $2.98 billion, a P/E ratio of 32.42, a P/E/G ratio of 1.32 and a beta of 0.53. The business’s 50-day moving average is $58.35 and its two-hundred day moving average is $67.32. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32.

Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. The company had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.Haemonetics’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts anticipate that Haemonetics Corporation will post 5.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HAE has been the subject of a number of research reports. Weiss Ratings cut shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $72.00 to $80.00 in a report on Friday. Barrington Research dropped their price objective on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a report on Tuesday, May 12th. BTIG Research restated a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a report on Friday, February 6th. Finally, Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $77.11.

View Our Latest Stock Analysis on Haemonetics

Haemonetics Profile

(Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.